Neuronetics Inc
NASDAQ:STIM
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Neuronetics Inc
NASDAQ:STIM
|
104m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
192B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.6B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.5B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
131.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
112.1B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.6B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
39.5B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Neuronetics Inc
Glance View
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 175 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Neuronetics Inc is -34.3%, which is above its 3-year median of -46.8%.
Over the last 3 years, Neuronetics Inc’s Net Margin has increased from -58.9% to -34.3%. During this period, it reached a low of -58.9% on Sep 30, 2022 and a high of -34.3% on Sep 30, 2025.
